The study objectiveis to perform clinical laboratory evaluation of the effectiveness of Prostatilen®ACand Arginine-zinc in treatment of patients with sperm pathology and concomitant varicocele and chronic nonbacterial prostatitis.Materials and methods.The study included 60 patients between 23 and 46 years of age. The first group included 30 patients (15 patients with varicocele and 15 patients with chronic nonbacterial prostatitis) who received Prostatilen®AC.The second group included 30 patients (15 patients with varicocele and 15 patients with chronic nonbacterial prostatitis) who received Arginine-zinc. Therapy duration was 20 days. Standard clinical and laboratory examination, spermiologic examination as well as measurement of antisperm antibodies, DNA fragmentation, oxidative stress level, cryotest, electron microscopy examination of the ejaculate were performed.Results.Five (5) days after the end of therapy, percentage of progressive motile sperm increased by 62 % in the Prostatilen®ACpatient group with chronic nonbacterial prostatitis (р <0.001) compared to the baseline, and by only 10 % in the Arginine-zinc patient group. Administration of Prostatilen®AClead to a more significant decrease of reactive oxygen intermediates in the ejaculate (р <0.001) and percentage of sperm with fragmented DNA (р <0.001) compared to administration of Arginine-zinc. The applied treatment schemes had no significant effect on the number of sperm with acrosomal hypoplasia. An anti-inflammatory effect of Prostatilen®ACwasalso identified (decreased number of leukocytes in sperm). During the study, 3 cases of adverse effects were registered: 1 after administration of Prostatilen®ACand2 after administration of Arginine-zinc.Conclusion.Prostatilen®ACcan be considered more effective and safer compared to Arginine-zinc for 20-day administration. In patients with sperm pathology, it more effectively improves sperm characteristics: increases sperm motility, sperm morphology, decreases DNA fragmentation and oxidative stress levels.
Introduction . In the initial stages of vasculogenic erectile dysfunction (ED), young men who are dissatisfied by administration of inhibitor 5-phosphodiesterase and/or intracavernous injections tend to deny surgical treatment. At the decompensated stage of ED penile prosthesis implantation presents the method of choice. However, currently there are new treatment approaches, the effectiveness of which is actively being investigated. Materials and methods . In article results of surgical treatment of 38 patients (25–48 years, mean age 34.3 ± 7.4 years) with vasculogenic ED are presented: 33 – venoocclusive ED, 5 – arterial insufficiency of the corpora cavernosa, 2 of them have hemodynamic and clinical signs of arteriovenous ED in subcompensation. The treatment included stenting or endovascular embolization with spirals. Results . Maximum follow-up was 4 years. Overall clinical effectiveness and subsequent sexual rehabilitation were assessed as sufficient based on the international index of erectile function before surgery was 10,5 ± 3,6 (9–13) and after surgery – 21,3 ± 4,2 (14–25) (p = 0,001). Conclusion . Application of these innovative technologies allows to perform a sexual rehabilitation of most patients with ED and to avoid phalloprosthesis implantation.
25 December 2019 in Complex Issues of Cardiovascular Diseases
The article presents the results of stenting of the left renal vein in 35 patients with proven hemodynamically significant compression of the vein in “aorto-mesenteric tweezers”. Clinical manifestations of lesions of the left renal vein are very diverse, and pathogenetic mechanisms remain not fully understood. Therefore, the determination of indications for stenting and perfect technical performance are predictors of success in the near and long-term periods of postoperative follow-up. Our experience in stenting the left renal vein demonstrates the possibility of achieving intraoperative technical success in 100 % of cases, as well as a significant improvement in the quality of life in most patients after endovascular intervention, due to a significant reduction in the clinical manifestations of the pathological phenomenon.
24 March 2021 in Complex Issues of Cardiovascular Diseases
May-Turner syndrome is a condition where the left common iliac vein is compressed between the lumbar spine and the overlying right common iliac artery. Left iliac vein compression is common (up to 24%) in the general population, but clinical manifestations occur in a few patients. This syndrome should be considered in case of unexplained edema of the left lower extremity since routine duplex ultrasound does not possess optimal sensitivity and specificity in the study of the iliac veins and the inferior vena cava. Intravascular ultrasound is the most accurate diagnostic method. However, the advent of computed tomography angiography and magnetic resonance angiography providing high-quality images of the vasculature have become a promising alternative to invasive intravascular ultrasound. Treatment for May-Turner syndrome usually involves stenting of the left common iliac vein along with medical therapy, including antithrombotic (anticoagulant and antiplatelet) therapy combined with phlebotonics. Our review reports modern methods of diagnosis and treatment of May-Turner syndrome.